Developing a regulatory compliant solution for nominal and accurate mass LC-MS spectrometry analysis in oligonucleotide therapeutics

Importance of the Topic

Oligonucleotide therapeutics represent a rapidly expanding class of biomolecules with growing clinical applications. Reliable characterization of these compounds by LC-MS is essential to ensure product identity, purity and consistent safety profiles. Compliance with regulatory guidelines, such as 21 CFR Part 11, mandates secure data handling, audit trails and controlled user access. Integrating high-resolution and nominal mass LC-MS workflows into a validated informatics platform addresses both scientific and compliance requirements for oligonucleotide analysis.

Objectives and Study Overview

This work describes the development and implementation of a regulatory-compliant solution for both nominal mass (single quadrupole) and accurate mass (QTOF) LC-MS/MS analysis of oligonucleotide therapeutics. The key goals were to integrate LabSolutions Insight Biologics software into the LabSolutions CS informatics environment, establish secure data management workflows, and demonstrate performance for sequence confirmation and impurity profiling of a phosphorothioate 20-mer oligonucleotide.

Methodology and Instrumentation

Data acquisition was performed on a Shimadzu Nexera XS UHPLC system coupled to either a Shimadzu LCMS-2050 single quadrupole or a Shimadzu LCMS-9050 QTOF instrument. Acquisition parameters included:

• LCMS-2050: Negative ion mode, m/z 600–2000, 1 s scan time, 1429 u/s scan speed.
• LCMS-9050: Negative ion TOF MS m/z 550–2500, DDA-MS/MS m/z 100–2800 (10 events, 0.1 s each), collision energy optimized by precursor m/z.

Raw data were captured and managed within LabSolutions CS, providing user authentication, project structure, secure archiving and audit trails. LabSolutions Insight Biologics served as a dedicated workspace for oligonucleotide processing, enabling sequence input, target modifications, and automated peak finding in nominal and high-resolution datasets.

Key Results and Discussion

Nominal mass data acquired on the LCMS-2050 allowed clear profiling of the full-length product and simple identification of sequence-related shortmers and longmers. High-resolution data from the LCMS-9050 QTOF enabled accurate mass confirmation of the target sequence and detailed characterization of low-level impurities. The combined workflow demonstrated:

• Accurate sequence confirmation through charge-state deconvolution and extracted ion chromatograms.
• Efficient impurity identification by data-dependent MS/MS spectra.
• Robust traceability via electronic audit trails that record all data processing and result modifications.

Benefits and Practical Applications of the Method

The integrated solution streamlines oligonucleotide analysis by centralizing data acquisition, processing and archiving. Key advantages include:

• Regulatory compliance through validated software controls and secure user management.
• Improved data integrity via versioned records and system activity logs.
• Enhanced throughput with automated peak processing tailored for nominal and accurate mass data.

Future Trends and Applications

Ongoing advances in high-resolution mass spectrometry and software-driven workflows will expand capabilities for longer sequences, modified backbones and complex impurity profiling. Cloud integration and AI-driven spectral interpretation promise further gains in throughput, automation and remote collaboration. Adapting compliant informatics platforms to emerging modalities such as ion mobility and native MS will broaden the analytical scope for next-generation oligonucleotide therapeutics.

Conclusion

The combined LabSolutions CS and Insight Biologics platform delivers a robust, 21 CFR Part 11-compliant workflow for both nominal and accurate mass LC-MS analysis of oligonucleotide therapeutics. The approach ensures secure data management, complete audit trails and reliable sequence confirmation, supporting quality control and regulatory submissions in oligonucleotide drug development.

References

No external literature citations provided in the original text.